Cerebral white matter hyperintensity in Parkinson's disease: A major risk factor for mild cognitive impairment

Parkinsonism and Related Disorders

Volumn 19, Issue 7, 2013, Pages 680-683

  Kandiah, Nagaendran ^a,b   Mak, Elijah ^a   Ng, Amanda ^a   Huang, Shan ^a   Au, Wing Lok ^a,b,c   Sitoh, Yih Yian ^a   Tan, Louis C S ^a,b,c  

^a National Neuroscience Institute   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c USA National Parkinson Foundation Centre of Excellence   (Singapore)

Author keywords

Cerebral small vessel disease; Mild cognitive impairment (MCI); Parkinson's disease; Volumetric MRI; White matter disease

Indexed keywords

LEVODOPA;

ADULT; AGE; ARTICLE; BRAIN DISEASE; BRAIN SIZE; BRAIN VENTRICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE CLASSIFICATION; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; FRONTAL CORTEX; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IDIOPATHIC DISEASE; LANGUAGE DISABILITY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL PERFORMANCE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; OCCIPITAL CORTEX; PARIETAL CORTEX; PARKINSON DISEASE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; WHITE MATTER HYPERINTENSITY;

AGED; ANALYSIS OF VARIANCE; CEREBRAL CORTEX; COGNITION DISORDERS; FEMALE; HUMANS; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NERVE FIBERS, MYELINATED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84878214877     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2013.03.008     Document Type: Article

References (20)

1. Aarsland D., Andersen K., Larsen J.P., Lolk A., Nielsen H., Kragh-Sorensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001, 56:730-736.
2. Jokinen P., Brück A., Aalto S., Forsback S., Parkkola R., Rinne J.O. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 2009, 15:88-93.
3. Poletti M., Emre M., Bonuccelli U. Mild cognitive impairment and cognitive reserve in Parkinson's disease. Parkinsonism Relat Disord 2011, 17:579-586.
4. Kandiah N., Narasimhalu K., Lau P.N., Seah S.H., Au W.L., Tan L.C. Cognitive decline in early Parkinson's disease. Mov Disord 2009, 24:605-608.
5. Caviness J.N., Driver-Dunckley E., Connor D.J., Sabbagh M.N., Hentz J.G., Noble B., et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007, 22:1272-1277.
6. Mamikonyan E., Moberg P.J., Siderowf A., Duda J.E., Have T.T., Hurtig H.I., et al. Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism Relat Disord 2009, 15:226-231.
7. Levy G., Schupf N., Tang M.X., Cote L.J., Louis E.D., Mejia H., et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 2002, 51:722-729.
8. Dalaker T.O., Larsen J.P., Dwyer M.G., Aarsland D., Beyer M.K., Alves G., et al. White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. Neuroimage 2009, 47:2083-2089.
9. Beyer M.K., Aarsland D., Greve O.J., Larsen J.P. Visual rating of white matter hyperintensities in Parkinson's disease. Mov Disord 2006, 21:223-229.
10. Lee S.J., Kim J.S., Yoo J.Y., Song I.U., Kim B.S., Jung S.L., et al. Influence of white matter hyperintensities on the cognition of patients with Parkinson disease. Alzheimer Dis Assoc Disord 2010, 24:227-233.
11. Gelb D.J., Oliver E., Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999, 56:33-39.
12. Tomlinson C.L., Stowe R., Patel S., Rick C., Gray R., Clarke C.E. Systematic review of Levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010, 25:2649-2685.
13. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state: a practical method for grading the cognitive state of patients for the clinicians. JPsychiatrRes 1975, 12:189-198.
14. Dalrymple-Alford J.C., MacAskill M.R., Nakas C.T., Livingston L., Graham C., Crucian G.P., et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010, 75:1717-1725.
15. Litvan I., Goldman J.G., Tröster A.I., Schmand B.A., Weintraub D., Petersen R.C., et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: movement Disorder Society Task Force guidelines. Mov Disord 2012, 27:349-356.
16. Emre M., Aarsland D., Brown R., Burn D.J., Duyckaerts C., Mizuno Y., et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007, 22:1689-1707.
17. Firbank M.J., Minett T., O'Brien J.T. Changes in DWI and MRS associated with white matter hyperintensities in elderly subjects. Neurology 2003, 61:950-954.
18. Sławek J., Roszmann A., Robowski P., Dubaniewicz M., Sitek E.J., Honczarenko K., et al. The impact of MRI white matter hyperintensities on dementia in Parkinson's disease in relation to the homocysteine level and other vascular risk factors. Neurodegener Dis Epub 2012 Jul 20.
19. Wang H.C., Hsu J.L., Leemans A. Diffusion tensor imaging of vascular Parkinsonism: structural changes in cerebral white matter and the association with clinical severity. Arch Neurol 2012, 23:1-9.
20. Shin J., Choi S., Lee J.E., Lee H.S., Sohn Y.J., Lee P.H. Subcortical white matter hyperintensities within the cholinergic pathways of Parkinson's disease patients according to cognitive status. JNeurol Neurosurg Psychiatr 2012, 83:315-321.